SEARCH:   Advanced

Blood, 10 September 2009, Vol. 114, No. 11, pp. 2273-2279. Prepublished online as a Blood First Edition Paper on July 13, 2009; DOI 10.1182/blood-2009-03-212191. This Article Full Text Full Text (PDF) Supplemental Tables and Figure All Versions of this Article: blood-2009-03-212191v1 114/11/2273    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Google Scholar Articles by Johnson, N. A. Articles by Horsman, D. E. PubMed PubMed Citation Articles by Johnson, N. A. Articles by Horsman, D. E. Related Collections Free Research Articles Lymphoid Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  LYMPHOID NEOPLASIA Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival Nathalie A. Johnson1,2, Kerry J. Savage3, Olga Ludkovski1, Susana Ben-Neriah1,2, Ryan Woods4, Christian Steidl1,2, Martin J. S. Dyer5, Reiner Siebert6, John Kuruvilla3, Richard Klasa3, Joseph M. Connors3, Randy D. Gascoyne1,2, and Douglas E. Horsman1,2 1 Department of Pathology, 2 Center for Translational and Applied Genomics, and Departments of 3 Medical Oncology and 4 Population Oncology, British Columbia Cancer Agency, Vancouver, BC; 5 Medical Research Council Toxicology Unit/University of Leicester, Leicester, United Kingdom; and 6 Institute of Human Genetics, Christian-Albrechts-University Kiel & University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany BCL2 and MYC are oncogenes commonly deregulated in lymphomas. Concurrent BCL2 and MYC translocations (BCL2+/MYC+) were identified in 54 samples by karyotype and/or fluorescence in situ hybridization with the aim of correlating clinical and cytogenetic characteristics to overall survival. BCL2+/MYC+ lymphomas were diagnosed as B-cell lymphoma unclassifiable (BCLU; n = 36) with features intermediate between Burkitt lymphoma and diffuse large B-cell lymphoma (DLBCL); DLBCL (n = 17), or follicular lymphoma (n = 1). Despite the presence of a t(14;18), 5 cases were BCL2 protein–negative. Nonimmunoglobulin gene/MYC (non-IG/MYC) translocations occurred in 24 of 54 cases (44%) and were highly associated with DLBCL morphology (P < .001). Over a median follow-up of 5.3 years, 6 patients remained in remission and 32 died within 6 months of the MYC+ rearrangement, irrespective of whether MYC+ occurred at diagnosis (31 of 54) or transformation (23 of 54; P = .53). A non-IG/MYC translocation partner, absent BCL2 protein expression and treatment with rituximab-based chemotherapy, were associated with a more favorable outcome, but a low International Prognostic Index score and DLBCL morphology were independent predictors of overall survival. A comprehensive cytogenetic analysis of BCL2 and MYC status on all aggressive lymphomas may identify a group of high-risk patients who may benefit from chemotherapeutic regimens that include rituximab and/or BCL2-targeted therapy. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: K. J. Savage, N. A. Johnson, S. Ben-Neriah, J. M. Connors, L. H. Sehn, P. Farinha, D. E. Horsman, and R. D. Gascoyne MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy Blood, October 22, 2009; 114(17): 3533 - 3537. [Abstract] [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020